IM Cannabis Board Changes Enhance Strategic Direction
IM Cannabis Corp. (NASDAQ: IMCC), a prominent player in the medical cannabis space, has recently announced significant changes to its Board of Directors. This restructuring aims to bolster the company's governance and strategic oversight as it navigates the evolving landscape of the cannabis industry.
New Appointments to the Board
As of mid-September 2025, the company has seen departures from its Board with the resignations of Messrs. Shmulik Arbel and Brian Schinderle. Their contributions have been acknowledged by Oren Shuster, the Chief Executive Officer of IMC. To maintain a robust leadership framework, the Board has appointed Asaf Yitzhaik and Eli Zamir as new members.
Experience and Expertise of New Board Members
Asaf Yitzhaik brings over thirty years of diverse experience spanning retail and real estate. He operates ASI Glasses, a well-established business in optics, and has a rich portfolio of real estate investments. His extensive involvement with multiple publicly traded companies highlights his capability in governance.
Eli Zamir also presents a wealth of expertise, particularly in finance and capital markets. His background includes significant roles, such as CEO of an underwriting firm and CFO of a public real estate entity. His leadership experience is expected to foster strong financial oversight and strategic growth.
Leadership Transitions and Future Strategies
Mr. Oz Adler, another director, has been appointed as the new Chairman of the Board, succeeding Oren Shuster, who will remain active as CEO. This leadership transition reflects IMC's commitment to advancing its strategic objectives while leveraging the operational excellence of its leadership team.
Strategic Review for Business Growth
In conjunction with these changes, IM Cannabis is pursuing additional business opportunities. The company aims to implement strategies that will facilitate long-term growth and enhance value for its shareholders. This strategic review includes exploring new avenues for business activities that could diversify and strengthen its market position.
About IM Cannabis Corp.
IM Cannabis Corp. operates in the medical cannabis sector, focusing on premium product delivery for therapeutic patients in key markets. Currently active in both Germany and Israel, IMC is dedicated to sustainable and profitable growth driven by a data-centric approach and exceptional product sourcing.
The company’s operational framework includes subsidiaries that manage distribution and logistics to ensure quality control and patient access across its targeted regions. In Germany, IMC's subsidiary, Adjupharm GmbH, plays a crucial role in supplying cannabis to pharmacies, thereby facilitating medical treatments for patients throughout the country.
Frequently Asked Questions
What led to the board changes at IM Cannabis Corp.?
The board changes are part of a strategic initiative to enhance governance and improve oversight as the company navigates future growth opportunities.
Who are the new members of the IM Cannabis Board?
The new members include Asaf Yitzhaik and Eli Zamir, both of whom bring extensive experience in business and finance.
What is the role of the new Chairman, Oz Adler?
Oz Adler will oversee the Board's functions and strategic direction, ensuring the company aligns with its growth objectives.
How does IM Cannabis plan to expand its business activities?
The company is conducting a strategic review to identify and explore potential new business avenues that could enhance shareholder value.
In which markets does IM Cannabis operate?
IM Cannabis primarily operates in Israel and Germany, focusing on the medical cannabis sector.
